BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock declined by 3.15% at last close whereas the BCLI stock price surges by 0.98% in the pre-market trading session. BrainStorm Cell Therapeutics Inc. is a pioneer in the development of novel autologous adult stem cell therapies for neurological disorders.
BCLI stock’ Significant Update
The scientific abstract “CSF biomarker correlations with the main result in NurOwn Phase 3 clinical trial” was published as a scientific poster at the completely digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) conference that took place on October 6, 2021, according to BrainStorm Cell Therapeutics. James Berry, M.D., MPH, Winthrop Family Scholar in ALS Sciences, Director of the Massachusetts General Hospital (MGH) interdisciplinary ALS clinic, and Chief of the Division of ALS and Motor Neuron Diseases, Boston MA, will do the session.
Three additional intrathecal infusions of NurOwn (MSC-NTF cells) were given with a difference of two months in the Phase 3 study (NCT03280056). It is used to treat amyotrophic lateral sclerosis (ALS) (ALS). Through the use of an unbiased linear logistic regression analysis, the session will highlight CSF biomarkers that exhibit excellent accuracy in predicting the major clinical result.
Chaim Lebovits, CEO of BrainStorm stated,
They are 100% devoted to advancing NurOwn, their unique cell therapy, in the treatment of ALS. Making major progress in ALS science and elucidating the molecular signature of NurOwn’s mode of action in ALS, they think, will be a critical next step in providing a much-needed medication to patients with ALS who have restricted treatment alternatives.
Stacy Lindborg, EVP and Head of Global Clinical Research at Brainstorm stated,
They’re pleased to demonstrate NurOwn’s large improvements in a variety of biomarkers encompassing critical domains including neurodegeneration, neuroinflammation, and neuroprotection. Moreover, they can accurately anticipate treatment results in the research utilizing biomarker response and a novel statistical approach. As they continue to explore and improve NurOwn, these objective biomarker endpoints provide them with more certainty.
